Findings provide proof-of-principle that AAV-mediated SIL1 gene therapy can prevent the neurological and muscular manifestations of Marinesco-Sjögren syndrome and identify Purkinje cells as a critical cellular target for preventing cerebellar dysfunction.
Abstract
Marinesco-Sjögren syndrome is a rare early-onset multisystem disorder characterized primarily by cerebellar ataxia and myopathy and caused by loss-of-function mutations in SIL1. No disease-modifying therapy is available. We investigated whether adeno-associated virus (AAV)-mediated gene therapy could prevent neurological and muscular disease in the woozy mouse model of SIL1 deficiency. Neonatal mice received intracerebroventricular injections of AAV-PHP.eB vectors expressing SIL1 under the control of either a ubiquitous or a Purkinje cell-specific promoter. Vehicle-treated woozy mice developed progressive motor impairment accompanied by extensive Purkinje cell degeneration, thinning of the cerebellar molecular layer, marked astrogliosis and activation of endoplasmic reticulum stress pathways. In contrast, AAV-SIL1 treatment prevented the onset of ataxia and substantially preserved cerebellar architecture, including Purkinje cells and molecular-layer thickness, while reducing astrogliosis and endoplasmic reticulum stress. Selective restoration of SIL1 expression in Purkinje cells was sufficient to rescue motor performance, supporting a major cell-autonomous contribution of Purkinje cell dysfunction to cerebellar disease. Therapeutic benefit was maintained throughout the 26-week observation period, the longest time point examined, with treated mice remaining behaviorally indistinguishable from heterozygous controls. AAV-SIL1 treatment also improved muscle function and markedly attenuated skeletal muscle pathology, with transgenic SIL1 expression in muscle reaching levels comparable to those in heterozygous controls. These findings provide proof-of-principle that AAV-mediated SIL1 gene therapy can prevent the neurological and muscular manifestations of Marinesco-Sjögren syndrome and identify Purkinje cells as a critical cellular target for preventing cerebellar dysfunction.
These findings establish CBLN1 deficiency as a cause of hereditary ataxia and identify extracellular CBLN1 replacement as a therapeutic strategy for a reversible cerebellar synaptopathy.
Tokiwa Yamasak, W. Kakegawa, Ayumi Hayashi et al.· Molecular Therapy· 0 citations
It is demonstrated that Ficd deletion mitigates the pathological decrease in myelin structural proteins and oligodendrocyte maturation factors, restoring levels of mature, myelinating oligodendrocytes and identifies FICD as a novel target for alleviating non-neuronal toxicity in SCA3.
K. V. Van Pelt, Ya-Mei Deng, A. Nesvizhskii et al.· bioRxiv· 0 citations
MEF2C haploinsufficiency syndrome is a severe neurodevelopmental disorder for which no disease-directed treatment is available. We investigated whether neuron-directed adeno-associated virus (AAV) delivery of a functional MEF2C coding sequence during the juvenile period could modify disease-relevant phenotypes in mice...
Zhuo-Lei Jiao, Cheng-Jie Yu, Tian-Shu Li et al.· bioRxiv· 0 citations
It is demonstrated that physiologically regulated FXN replacement is sufficient to achieve substantial functional rescue in FA, supporting a gene therapy strategy based on a transgene expression driven by endogenous regulatory elements.
Federica Pilotto, Laure Dall'Agnol, L. Reutenauer et al.· Human Gene Therapy· 0 citations
A knock-in mouse line at the Gt(ROSA)26Sor (Rosa26) locus carrying a single-copy, 11-kb human SOD1 genomic fragment, including all exons and introns, with the L126S mutation is generated, providing a versatile and clinically relevant platform for the preclinical evaluation of genome-editing therapies targeting heterozy...
T. Okunomiya, Tomoki Sakasai, Kayoko Tsukita et al.· Experimental animals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.